首页> 美国卫生研究院文献>Oxford Open >541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load CD4+ Count and WHO Clinical Staging

【2h】

541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load CD4+ Count and WHO Clinical Staging

机译：541.初次接受HIV-1治疗的患者中的达鲁那韦/库比斯他汀/恩曲他滨/替诺福韦阿芬酯：基于基线病毒载量CD4 +计数和WHO临床分期的亚组第48周结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundDarunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen approved in Europe and under regulatory review in the United States for the treatment of HIV-1 infection. In the pivotal AMBER trial in antiretroviral treatment (ART)-naïve, HIV-1–infected adults, D/C/F/TAF achieved a high virologic response rate at Week 48 that was noninferior to control (D/C+F/tenofovir disoproxil fumarate); favorable renal/bone outcomes were seen with D/C/F/TAF vs. control. These results were consistent across age, gender, and race subgroups. Here we report Week 48 results in subgroups based on viral load (VL), CD4⁺ count, and WHO clinical staging of HIV/AIDS at baseline.

机译：背景Darunavir / cobicistat / emtricitabine / tenofovir alafenamide（D / C / F / TAF）800/150/200/10 mg是每日一次的单片治疗方案，已在欧洲获批，并在美国接受有关法规的审查，用于治疗HIV-1感染。在未经抗逆转录病毒治疗（ART）且未感染HIV-1的成年人的关键性AMBER试验中，D / C / F / TAF在第48周达到了较高的病毒学应答率，这不亚于对照（D / C + F / tenofovir富马酸二甲吡酯）; D / C / F / TAF与对照组相比，肾/骨预后良好。这些结果在年龄，性别和种族亚组中都是一致的。在这里，我们根据病毒载量（VL），CD4 ^{+ 计数以及基线时WHO / HIV / AIDS的临床分期报告了第48周的亚组。}

著录项

期刊名称 Oxford Open
作者
Christoph D Spinner; Bruce Rashbaum; Cheryl Mcdonald; Cristina Mussini; Donghan Luo; John Jezorwski; Kimberley Brown; Eric Y Wong;
展开▼
作者单位

展开▼
年(卷),期 -1(5),Suppl 1
年度 -1
页码 S201
总页数 1
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients [J] . Eron Joseph J., Orkin Chloe, Gallant Joel, AIDS . 2018,第11期

机译：一周为期48次随机相3阶段试验Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenainide治疗 - 幼稚HIV-1患者
2. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients [J] . AIDS . 2020,第5期

机译：第96周96阶段3阶段试验Darunavir / Cobicistat / Emtricisabine / Tenofovir AlafenaMide治疗 - 幼稚HIV-1患者
3. Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [J] . Margot Nicolas A., Kitrinos Kathryn M., Fordyce Marshall, HIV clinical trials . 2016,第2期

机译：接受Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide治疗48周后，未接受过HIV-1治疗的患者很少出现耐药性
4. SVM-enabled prognostic method for clinical decision making: The use of CD4 T-cell level and HIV-1 viral load for guiding treatment initiation and alteration [C] . Kasmiran Khairul A, Zomaya Albert Y, Mazari Ali A, 23rd IEEE International Symposium on Computer-Based Medical Systems . 2010

机译：支持SVM的临床决策预后方法：使用CD4 T细胞水平和HIV-1病毒载量指导治疗的开始和改变
5. 887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial [O] . Gregory D Huhn, Moti Ramgopal, Gordon Crofoot, -1

机译：887.在达那鲁韦/库比西他/艾美他他滨/替诺福韦阿拉芬酰胺（D / C / F / TAF）的单片治疗方案（STR）中HIV-1感染的成年人快速开始抗逆转录病毒疗法（ART）的病毒学抑制率很高800 / 150/200/10 mg与基线疾病特征无关：第3 DIAMOND试验的第48周亚组分析
6. 887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial [O] . Gregory D Huhn, Moti Ramgopal, Gordon Crofoot, 2019

机译：887. HIV-1感染的成年人达到的病毒学抑制率快速启动抗逆转录病毒治疗（ART）与达尔努纳夫/钴/卵巢/ Emtrickabine / Tenofovir Alafenide（D / C / F / TAF）800 / 150/200 / 10 mg无论基线疾病特征如何：第48周亚组分析了第3阶段钻石试验

541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load CD4+ Count and WHO Clinical Staging

摘要

著录项

相似文献

相关主题

期刊订阅